Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQPH29)

• Drug Name: Curcumin Drug Info
• Synonyms: curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Turmeric yellow; Turmeric; Curcuma; Kacha haldi; Gelbwurz; Indian saffron; Curcumin I; Souchet; Halud; Halad; Haidr; Haldar; Merita earth; Yellow Ginger; Terra Merita; Yellow Root; Safran d'Inde; Yo-Kin; Golden seal; Curcuma oil; Orange Root; Oils, curcuma; CI Natural Yellow 3; Curcumine; Hydrastis; Indian turmeric; Yellow puccoon; Turmeric extract; Diferaloylmethane; Kurkumin [Czech]; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Tumeric yellow; Turmeric oil

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 3	[1] , [2]

• Cross-matching ID:
  PubChem CID: 969516
  ChEBI ID: CHEBI:3962
  CAS Number: CAS 458-37-7
  TTD Drug ID: DMQPH29
  VARIDT Drug ID: DR00559
  INTEDE Drug ID: DR1941

Molecule-Related Drug Atlas

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A1 (UGT1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[16]
Estradiol	DMUNTE3	Breast cancer	2C60-2C65	Approved	[17]
Acetaminophen	DMUIE76	Pain	MG30-MG3Z	Approved	[18]
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Mycophenolate mofetil	DMPQAGE	Organ transplant rejection	NE84	Approved	[22]
Metronidazole	DMTIVEN	Amoebiasis	1A36	Approved	[23]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[24]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[25]

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A9 (UGT1A9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Pain	MG30-MG3Z	Approved	[26]
Diclofenac	DMPIHLS	Osteoarthritis	FA00-FA05	Approved	[27]
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[28]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[29]
Mycophenolate mofetil	DMPQAGE	Organ transplant rejection	NE84	Approved	[30]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[29]
Ibuprofen	DM8VCBE	Pain	MG30-MG3Z	Approved	[29]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[31]
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[29]
Haloperidol	DM96SE0	Schizophrenia	6A20	Approved	[29]

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A8 (UGT1A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Cutaneous T-cell lymphoma	2B01	Approved	[32]
Empagliflozin	DMRF9YK	Type-1 diabetes	5A10	Approved	[33]
Darolutamide	DMV7YFT	Prostate cancer	2C82.0	Approved	[34]
Afimoxifene	DMFORDT	Breast cancer	2C60-2C65	Phase 2	[35]
Eugenol	DM7US1H	Discovery agent	N.A.	Patented	[14]
Chrysin	DM7V2LG	Discovery agent	N.A.	Investigative	[14]
Phloretin	DMYA50U	Discovery agent	N.A.	Investigative	[14]
Anthraflavic acid	DMN1YFU	Discovery agent	N.A.	Investigative	[14]
Cis-4-hydroxytamoxifen	DMRFTB5	Discovery agent	N.A.	Investigative	[35]

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A7 (UGT1A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Cutaneous T-cell lymphoma	2B01	Approved	[32]
Eugenol	DM7US1H	Discovery agent	N.A.	Patented	[14]
Chrysin	DM7V2LG	Discovery agent	N.A.	Investigative	[14]
Phloretin	DMYA50U	Discovery agent	N.A.	Investigative	[14]
Anthraflavic acid	DMN1YFU	Discovery agent	N.A.	Investigative	[14]

Drug(s) Metabolized By NADPH-dependent curcumin reductase (curA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[15]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Bacterial infection	1A00-1C4Z	Approved	[36]
Doxorubicin	DMVP5YE	Solid tumour/cancer	2A00-2F9Z	Approved	[37]
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[13]
Folic acid	DMEMBJC	Folate-deficiency anemia	3A02.Y	Approved	[38]
Fluorouracil	DMUM7HZ	Solid tumour/cancer	2A00-2F9Z	Approved	[13]
Cisplatin	DMRHGI9	Solid tumour/cancer	2A00-2F9Z	Approved	[13]
Progesterone	DMUY35B	Premature labour	JB00	Approved	[39]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[13]
Estradiol	DMUNTE3	Breast cancer	2C60-2C65	Approved	[40]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[41]

Drug(s) Targeting Nitric-oxide synthase inducible (NOS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SD-6010	DM9DEYL	Osteoarthritis	FA00-FA05	Phase 3	[42]
MPL-S	DMNDCFY	Endotoxic shock	1G41	Phase 3	[43]
Pimagedine HCl	DMPWH30	Diabetic kidney disease	GB61.Z	Phase 2/3	[44]
GW274150	DMZMCB1	Asthma	CA23	Phase 2	[45]
BXT-51072	DMD8GNB	Cardiovascular disease	BA00-BE2Z	Phase 2	[46]
HP-228	DMNZ35F	Postoperative pain	MG30-MG3Z	Phase 2	[47]
CR-3294	DMHJEZS	Diarrhea	ME05.1	Phase 2	[48]
KD-7040	DME1WV2	Pain	MG30-MG3Z	Phase 2	[49]
LT-1951	DM5N04G	Coronary artery disease	BA80	Phase 1/2	[50]
Aminoguanidine	DMJQDUC	Diabetic retinopathy	9B71.0	Phase 1	[51]

Drug(s) Targeting Carbonic anhydrase VI (CA-VI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Seborrhoeic dermatitis	EA81	Approved	[52]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[53]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[54]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[55]
SAR566658	DM6Q295	Solid tumour/cancer	2A00-2F9Z	Phase 2	[56]
Ferulic Acid	DMJC7NF	Discovery agent	N.A.	Patented	[54]
Spermine	DMD4BFY	N. A.	N. A.	Terminated	[57]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[54]
Coumarin	DM0N8ZM	Discovery agent	N.A.	Investigative	[58]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Carbonic anhydrase I (CA-I)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Seborrhoeic dermatitis	EA81	Approved	[52]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[59]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[59]
Methazolamide	DM7J2TA	Glaucoma/ocular hypertension	9C61	Approved	[60]
Acetazolamide	DM1AF5U	Glaucoma/ocular hypertension	9C61	Approved	[59]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[54]
CG-100649	DMIKMA9	Arthritis	FA20	Phase 3	[61]
Phenol	DM1QSM3	N. A.	N. A.	Phase 2/3	[5]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[55]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[62]

Drug(s) Targeting Multidrug resistance protein (MDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benzquinamide	DMU4D5Y	Nausea	MD90	Approved	[63]
Ortataxel	DM1EK5D	Solid tumour/cancer	2A00-2F9Z	Phase 2	[64]
MM36	DM6VPIO	Atopic dermatitis	EA80	Phase 2	[9]
Valspodar	DMXRU9M	Acute myeloid leukaemia	2A60	Discontinued in Phase 3	[65]
WK-X-34	DMX0ZBC	Discovery agent	N.A.	Investigative	[9]
KP772	DMUZSJ2	Discovery agent	N.A.	Investigative	[9]
Chemosensitizers	DMYSG9J	Discovery agent	N.A.	Investigative	[66]

Drug(s) Targeting Carbonic anhydrase XII (CA-XII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Seborrhoeic dermatitis	EA81	Approved	[52]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[67]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[54]
Phenol	DM1QSM3	N. A.	N. A.	Phase 2/3	[5]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[55]
Ferulic Acid	DMJC7NF	Discovery agent	N.A.	Patented	[54]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[54]
Coumarin	DM0N8ZM	Discovery agent	N.A.	Investigative	[58]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[5]
GALLICACID	DM6Y3A0	Discovery agent	N.A.	Investigative	[54]

Drug(s) Targeting Carbonic anhydrase II (CA-II)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Seborrhoeic dermatitis	EA81	Approved	[52]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[67]
Dorzolamide	DMA17D0	Open-angle glaucoma	9C61	Approved	[68]
Chlorothiazide	DMLHESP	Congestive heart failure	BD10	Approved	[69]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[70]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[70]
Cyclothiazide	DMJ4AWC	Congestive heart failure	BD10	Approved	[71]
Ethinamate	DMK57GB	Insomnia	7A00-7A0Z	Approved	[72]
Benzthiazide	DMQWZ0H	High blood pressure	BA00	Approved	[73]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[54]

Drug(s) Targeting Carbonic anhydrase XIV (CA-XIV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[74]
Trientine	DMD2WPG	Inborn error of metabolism	5C50-5C59	Approved	[57]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[54]
Phenol	DM1QSM3	N. A.	N. A.	Phase 2/3	[5]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[55]
Ferulic Acid	DMJC7NF	Discovery agent	N.A.	Patented	[54]
Spermine	DMD4BFY	N. A.	N. A.	Terminated	[57]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[54]
Coumarin	DM0N8ZM	Discovery agent	N.A.	Investigative	[58]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Matrix metalloproteinase-13 (MMP-13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apratastat	DM8W4N9	Rheumatoid arthritis	FA20	Phase 2	[75]
PMID17935984C1	DMO1IHL	Pain	MG30-MG3Z	Clinical trial	[76]
PMID29130358-Compound-Figure18(14a)	DMHIBTZ	N. A.	N. A.	Patented	[77]
PMID29130358-Compound-Figure16(9b)	DMPAQLZ	N. A.	N. A.	Patented	[77]
PMID29130358-Compound-Figure16(9a)	DMKX5R8	N. A.	N. A.	Patented	[77]
PMID29130358-Compound-Figure18(14)	DM7WXJ9	N. A.	N. A.	Patented	[77]
PMID29130358-Compound-Figure16(9c)	DM0ZRI9	N. A.	N. A.	Patented	[77]
GM6001	DM7V9CT	Corneal ulcer	9A76	Discontinued in Phase 2	[78]
RS-130830	DMOTANY	Hepatitis C virus infection	1E51.1	Discontinued in Phase 2	[79]
MMI270	DM38N2K	Discovery agent	N.A.	Investigative	[80]

Drug(s) Targeting Albendazole monooxygenase (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMX-53	DMZUAJ4	Atopic dermatitis	EA80	Phase 2	[81]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[82]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[70]
ML-3163	DM3S5UC	Discovery agent	N.A.	Investigative	[83]
6-(3-Hydroxy-phenyl)-naphthalen-2-ol	DMH8WA2	Discovery agent	N.A.	Investigative	[84]
2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole	DMZVBPG	Discovery agent	N.A.	Investigative	[85]
ML-3375	DMXJY6W	Discovery agent	N.A.	Investigative	[83]
ML-3403	DMTQWI8	Discovery agent	N.A.	Investigative	[83]
4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol	DM7ERYJ	Discovery agent	N.A.	Investigative	[86]
2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol	DMUGAT8	Discovery agent	N.A.	Investigative	[86]

Drug(s) Targeting Xanthine dehydrogenase/oxidase (XDH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopurinol	DMLPAOB	Hyperuricaemia	5C55.Y	Approved	[87]
Febuxostat	DMDEXQ0	Hyperuricaemia	5C55.Y	Approved	[88]
Fosdenopterin	DMR0TYK	Molybdenum cofactor deficiency	5B5K.A	Approved	[89]
Oxypurinol	DMURH4X	Heart failure	BD10-BD13	Phase 2/3	[90]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[91]
Topiroxostat	DMA04DE	Gout	FA25	Phase 2	[92]
TMX-049	DME8PFQ	Diabetic nephropathy	GB61.Z	Phase 2	[93]
LC-350189	DMHT3CB	Gout	FA25	Phase 1	[94]
Azaindole derivative 5	DMD2BL3	N. A.	N. A.	Patented	[95]
Fused heterocyclic compound 3	DM2QVHY	N. A.	N. A.	Patented	[95]

Drug(s) Targeting Carbonic anhydrase (CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Seborrhoeic dermatitis	EA81	Approved	[96]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[53]
Quinethazone	DMWCOSR	Hypertension	BA00-BA04	Approved	[97]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[54]
Phentermine+topiramate	DMVEHM4	Obesity	5B81	Phase 3	[98]
Phenol	DM1QSM3	N. A.	N. A.	Phase 2/3	[5]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[55]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[99]
Ferulic Acid	DMJC7NF	Discovery agent	N.A.	Patented	[54]
PMID30074415-Compound-21	DM3NPOU	N. A.	N. A.	Patented	[100]

Drug(s) Targeting Carbonic anhydrase IV (CA-IV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Seborrhoeic dermatitis	EA81	Approved	[52]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[101]
Brinzolamide	DMBAPFG	Open-angle glaucoma	9C61	Approved	[59]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[54]
Phenol	DM1QSM3	N. A.	N. A.	Phase 2/3	[5]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[55]
Sodium pyruvate	DMST6A3	Asthma	CA23	Phase 1/2	[102]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[99]
Ferulic Acid	DMJC7NF	Discovery agent	N.A.	Patented	[54]
Spermine	DMD4BFY	N. A.	N. A.	Terminated	[57]

Drug(s) Targeting Matrix metalloproteinase-9 (MMP-9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DP-b99	DM97S10	Stroke	8B20	Phase 3	[103]
GS-5745	DMP8MDW	Gastric adenocarcinoma	2B72	Phase 3	[104]
Andecaliximab	DMLDB1X	Gastric adenocarcinoma	2B72	Phase 3	[105]
BLZ-100	DMFKA4G	Glioma	2A00.0	Phase 1/2	[106]
Neovastat	DMXTYWJ	Non-small-cell lung cancer	2C25.Y	Phase 1	[107]
PMID29130358-Compound-Figure18(14a)	DMHIBTZ	N. A.	N. A.	Patented	[77]
PMID29130358-Compound-Figure17(12)	DMML4PA	N. A.	N. A.	Patented	[77]
PMID29130358-Compound-Figure17(10)	DMVA15O	N. A.	N. A.	Patented	[77]
PMID29130358-Compound-SB-3CT	DMC64XQ	N. A.	N. A.	Patented	[77]
PMID29130358-Compound-Figure17(11)	DMSZA9L	N. A.	N. A.	Patented	[77]

Drug(s) Targeting Prostaglandin G/H synthase 1 (COX-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Seborrhoeic dermatitis	EA81	Approved	[108]
Naproxen	DMZ5RGV	Osteoarthritis	FA00-FA05	Approved	[109]
Mesalazine	DMOL5IU	Ulcerative colitis	DD71	Approved	[110]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[111]
Bromfenac	DMKB79O	Postoperative inflammation	1A00-CA43.1	Approved	[112]
Aminosalicylic acid	DMENSL5	Inflammatory bowel disease	DD72	Approved	[59]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[113]
Piroxicam	DMTK234	Pain	MG30-MG3Z	Approved	[59]
Suprofen	DMKXJZ7	Miosis	LA11.62	Approved	[114]
Gamma-homolinolenic acid	DMSXKYG	Malnutrition	5B50-5B71	Approved	[115]

Drug(s) Targeting Carbonic anhydrase IX (CA-IX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[54]
Phenol	DM1QSM3	N. A.	N. A.	Phase 2/3	[5]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[55]
Indisulam	DM9SX6Y	Lymphoma	2A80-2A86	Phase 2	[116]
Girentuximab I-124	DMG3O2Z	Renal cell carcinoma	2C90	Phase 2	[117]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[118]
BAY 79-4620	DM14XQN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[119]
90Y-cG250	DMJR6TC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[120]
Ferulic Acid	DMJC7NF	Discovery agent	N.A.	Patented	[54]
PMID30074415-Compound-GS3	DM2G8DN	N. A.	N. A.	Patented	[100]

Drug(s) Targeting DNA [cytosine-5]-methyltransferase 3B (DNMT3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID27376512-Compound-MTC-424	DMGNRZU	N. A.	N. A.	Patented	[121]
PMID27376512-Compound-MTC-427	DMWXEZD	N. A.	N. A.	Patented	[121]
PMID27376512-Compound-MTC-422	DM1MVQD	N. A.	N. A.	Patented	[121]
PMID27376512-Compound-MTC-423	DM9RSDX	N. A.	N. A.	Patented	[121]
(L-)-S-adenosyl-L-homocysteine	DMDUN83	Discovery agent	N.A.	Investigative	[122]
NSC-622445	DME35CB	Discovery agent	N.A.	Investigative	[6]
NSC-622444	DMM5UT9	Discovery agent	N.A.	Investigative	[6]
NSC-138419	DMH684Q	Discovery agent	N.A.	Investigative	[6]
NSC-319745	DMF3G06	Discovery agent	N.A.	Investigative	[6]
NSC-348926	DM3TDEO	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting Prostaglandin G/H synthase 2 (COX-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Pain	MG30-MG3Z	Approved	[123]
Naproxen	DMZ5RGV	Osteoarthritis	FA00-FA05	Approved	[109]
Etodolac	DM6WJO9	Pain	MG30-MG3Z	Approved	[124]
Indomethacin	DMSC4A7	Rheumatoid arthritis	FA20	Approved	[59]
Celecoxib	DM6LOQU	Rheumatoid arthritis	FA20	Approved	[125]
Nabumetone	DMAT2XH	Pain	MG30-MG3Z	Approved	[126]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[127]
Flurbiprofen	DMGN4BY	Rheumatoid arthritis	FA20	Approved	[128]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[111]
Aminosalicylic acid	DMENSL5	Inflammatory bowel disease	DD72	Approved	[59]

Drug(s) Targeting Amyloid beta A4 protein (APP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Florbetapir F-18	DMJ8A3Z	Diagnostic imaging	N.A.	Approved	[129]
PF-03084014	DMUP5Z0	Desmoid tumour	2F7C	Phase 3	[130]
Solanezumab	DM0HIU5	Alzheimer disease	8A20	Phase 3	[131]
BIIB037	DM51JW4	Alzheimer disease	8A20	Phase 3	[132]
Tramiprosate	DM7BSRH	Alzheimer disease	8A20	Phase 3	[133]
Bapineuzumab	DMHQ5GK	Alzheimer disease	8A20	Phase 3	[134]
ALZT-OP1	DMG5BTD	Alzheimer disease	8A20	Phase 3	[135]
Gantenerumab	DMWX90U	Alzheimer disease	8A20	Phase 3	[136]
Crenezumab	DM7QI29	Alzheimer disease	8A20	Phase 3	[137]
NI-101	DMJ2KIE	Alzheimer disease	8A20	Phase 3	[138]

Drug(s) Targeting DNA [cytosine-5]-methyltransferase (DNMT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Azacitidine	DMTA5OE	Myelodysplastic syndrome	2A37	Approved	[139]
S-110	DMXY34J	Acute myeloid leukaemia	2A60	Phase 3	[140]
ASTX727	DM4HK8Z	Chronic myelogenous leukaemia	2A20.0	Phase 3	[130]
PMID27376512-Compound-PG-11047	DM5K4YF	N. A.	N. A.	Patented	[121]
PMID27376512-Compound-PG-11048	DM3U7RN	N. A.	N. A.	Patented	[121]
PMID27376512-Compound-MTC-434	DM70CTE	N. A.	N. A.	Patented	[121]
PMID27376512-Compound-CROs	DMBFUTL	N. A.	N. A.	Patented	[121]
(L-)-S-adenosyl-L-homocysteine	DMDUN83	Discovery agent	N.A.	Investigative	[122]
NSC-622445	DME35CB	Discovery agent	N.A.	Investigative	[6]
NSC-622444	DMM5UT9	Discovery agent	N.A.	Investigative	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Albendazole monooxygenase (CYP3A4)	TTXV4FI	CP3A4_HUMAN	Inhibitor	[3]
Amyloid beta A4 protein (APP)	TTE4KHA	A4_HUMAN	Inhibitor	[4]
Carbonic anhydrase (CA)	TTUNARX	NOUNIPROTAC	Inhibitor	[5]
Carbonic anhydrase I (CA-I)	TTHQPL7	CAH1_HUMAN	Inhibitor	[5]
Carbonic anhydrase II (CA-II)	TTANPDJ	CAH2_HUMAN	Inhibitor	[5]
Carbonic anhydrase IV (CA-IV)	TTZHA0O	CAH4_HUMAN	Inhibitor	[5]
Carbonic anhydrase IX (CA-IX)	TT2LVK8	CAH9_HUMAN	Inhibitor	[5]
Carbonic anhydrase VI (CA-VI)	TTCFSPE	CAH6_HUMAN	Inhibitor	[5]
Carbonic anhydrase XII (CA-XII)	TTSYM0R	CAH12_HUMAN	Inhibitor	[5]
Carbonic anhydrase XIV (CA-XIV)	TTEYTKG	CAH14_HUMAN	Inhibitor	[5]
DNA [cytosine-5]-methyltransferase (DNMT)	TTHVCUP	NOUNIPROTAC	Inhibitor	[6]
DNA [cytosine-5]-methyltransferase 3B (DNMT3B)	TT6VZ78	DNM3B_HUMAN	Inhibitor	[6]
Matrix metalloproteinase-13 (MMP-13)	TTHY57M	MMP13_HUMAN	Inhibitor	[7]
Matrix metalloproteinase-9 (MMP-9)	TT6X50U	MMP9_HUMAN	Inhibitor	[8]
Multidrug resistance protein (MDR)	TT0JLSD	NOUNIPROTAC	Inhibitor	[9]
Nitric-oxide synthase inducible (NOS2)	TTF10I9	NOS2_HUMAN	Inhibitor	[10]
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[11]
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[11]
Xanthine dehydrogenase/oxidase (XDH)	TT7RJY8	XDH_HUMAN	Inhibitor	[12]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[13]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[14]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[14]
UDP-glucuronosyltransferase 1A8 (UGT1A8)	DE2GB8N	UD18_HUMAN	Substrate	[14]
UDP-glucuronosyltransferase 1A7 (UGT1A7)	DEZO4N3	UD17_HUMAN	Substrate	[14]
NADPH-dependent curcumin reductase (curA)	DEZWDKE	CURA_ECOLI	Substrate	[15]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7000).
• [2] Nanocurcumin: a promising therapeutic advancement over native curcumin. Crit Rev Ther Drug Carrier Syst. 2013;30(4):331-68.
• [3] Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31.
• [4] Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9.
• [5] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [6] Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
• [7] High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
• [8] Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6.
• [9] Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74.
• [10] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [11] Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammator... Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7.
• [12] Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
• [13] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [14] Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
• [15] Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6615-20.
• [16] Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
• [17] Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
• [18] Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
• [19] UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
• [20] Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
• [21] Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
• [22] Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
• [23] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [24] Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
• [25] Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
• [26] Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
• [27] Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
• [28] Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
• [29] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [30] The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
• [31] The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
• [32] Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr;6(4):563-85.
• [33] Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
• [34] Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
• [35] Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
• [36] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [37] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [38] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [39] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [40] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [41] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [42] A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95.
• [43] Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun. 1997 Aug;65(8):3239-47.
• [44] Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res. 2008 Sep 16;1230:138-49.
• [45] GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003 Mar;63(3):853-65.
• [46] Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1880-8.
• [47] HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J Pharmacol Exp Ther. 1995 Nov;275(2):584-91.
• [48] Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol. 2010 October; 66(5): 819-827.
• [49] WO patent application no. 2014,0214,08, Method for treating cancer by anticancer agent co-administration.
• [50] Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14.
• [51] Inhibitory effects of aminoguanidine on thyroid follicular carcinoma development in inflamed capsular regions of rats treated with sulfadimethoxine... Cancer Sci. 2009 Oct;100(10):1794-800.
• [52] Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
• [53] Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
• [54] Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
• [55] Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
• [56] An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. Mol Cancer Ther. 2020 Aug;19(8):1660-1669.
• [57] Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
• [58] Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
• [59] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [60] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
• [61] Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
• [62] Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
• [63] Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells. Oncol Res. 1992;4(8-9):359-65.
• [64] Clinical pipeline report, company report or official report of Spectrum Phamaceuticals (2009).
• [65] Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15. Jpn J Cancer Res. 2001 Oct;92(10):1116-26.
• [66] P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets. 2000 Jul;1(1):85-99.
• [67] Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
• [68] Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
• [69] Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
• [70] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [71] Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
• [72] Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
• [73] Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
• [74] Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
• [75] Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
• [76] Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34.
• [77] Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
• [78] Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia si... J Biol Chem. 2007 Sep 21;282(38):27781-91.
• [79] Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
• [80] Heterocycle-based MMP inhibitors with P2' substituents. Bioorg Med Chem Lett. 2001 Apr 23;11(8):1009-13.
• [81] Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
• [82] Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)py... J Med Chem. 2008 Oct 9;51(19):5897-900.
• [83] Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
• [84] Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
• [85] Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
• [86] New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
• [87] Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
• [88] Clinical pipeline report, company report or official report of Takeda (2009).
• [89] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [90] Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
• [91] Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
• [92] QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
• [93] Clinical pipeline report, company report or official report of Teijin Pharma.
• [94] Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.
• [95] An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
• [96] Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
• [97] Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73.
• [98] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [99] Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
• [100] Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
• [101] Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
• [102] Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8.
• [103] DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789.
• [104] National Cancer Institute Drug Dictionary (drug id 747683).
• [105] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [106] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [107] Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
• [108] The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
• [109] Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
• [110] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [111] Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
• [112] Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
• [113] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [114] Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
• [115] Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
• [116] Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-assoc... Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23.
• [117] Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407.
• [118] Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbo... Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71.
• [119] Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9.
• [120] Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013 May 29;14(6):11402-23.
• [121] DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
• [122] Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2742-6.
• [123] Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
• [124] Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
• [125] Pfizer. Product Development Pipeline. March 31 2009.
• [126] Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
• [127] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [128] Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
• [129] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [130] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [131] Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21.
• [132] Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18.
• [133] Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47.
• [134] Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82.
• [135] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [136] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [137] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
• [138] Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther. 2013; 7: 1471-1479.
• [139] The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid l... Leukemia. 2009 Jun;23(6):1019-28.
• [140] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)